Clovis Oncology Announces 2020 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Clovis Oncology (CLVS) Misses Q4 EPS by 25c
February 23, 2021 8:02 AM ESTClovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.02), $0.25 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $43.3 million versus the consensus estimate of $43.22 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More